AEHR at 18.59X Sales: Market Loves Its AI Story, But is Love Blind?

AEHR has rallied 363% in 2026 on surging demand for AI semiconductor testing equipment, but the stock now trades at 18.59 times forward sales—more than triple its historical median valuation. The company carries a $100.6 million backlog, yet the premium multiple leaves little room for missteps.

Zacks Investment Research assigns AEHR a Rank #3 (Hold), citing execution risk and valuation stretch. The company derives 70% of revenue from its top five customers, creating concentrated exposure if any relationship weakens or if chip capital spending cycles down. That customer concentration amplifies downside risk in a sector known for sharp demand swings.

Analysts remain constructive on the AI-driven testing opportunity, but the current price appears to discount flawless execution and sustained CapEx from a narrow base of buyers. Any order pushout or margin pressure could compress the multiple quickly.